Bastiaan Sallevelt

26 CHAPTER 1 33. Lombardi F, Paoletti L, Carrieri B, Dell’Aquila G, Fedecostante M, Di Muzio M, et al. Underprescription of medications in older adults: causes, consequences and solutions—a narrative review. Eur Geriatr Med 2021;12:453–62. s41999-021-00471-x. 34. Kuijpers MAJ, Van Marum RJ, Egberts ACG, Jansen PAF. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008;65:130–3. https://doi. org/10.1111/j.1365-2125.2007.02961.x. 35. Cherubini A, Corsonello A, Lattanzio F. Underprescription of beneficial medicines in older people: Causes, consequences and prevention. Drugs and Aging 2012;29:463–75. 36. Márquez PHP, Torres OH, San-José A, Vidal X, Agustí A, Formiga F, et al. Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study. Drugs and Aging 2017;34:453–66. https://doi. org/10.1007/s40266-017-0452-z. 37. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007;370:173–84. 38. Buetow SA, Sibbald B, Cantrill JA, Halliwell S. Appropriateness in health care: Application to prescribing. Soc Sci Med 1997;45:261–71. 39. De Vries T, Henning R, Hogerzeil H, Fresle D. Guide to Good Prescribing. World Health Organization (WHO). 1995:1–142. (accessed May 30, 2022). 40. Keijsers CJPW, Segers WS, De Wildt DJ, Brouwers JRBJ, Keijsers L, Jansen PAF. Implementation of the WHO-6-step method in the medical curriculum to improve pharmacology knowledge and pharmacotherapy skills. Br J Clin Pharmacol 2015;79:896– 906. 41. Tichelaar J, Richir MC, Garner S, Hogerzeil H, de Vries TPGM. WHO guide to good prescribing is 25 years old: quo vadis? Eur J Clin Pharmacol 2020;76:507–13. https:// 42. Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet 2017;389(1008:1778– 80. 43. Payne RA. The epidemiology of polypharmacy. Clin Med J R Coll Physicians London 2016;16:465–9. 44. Hughes LD, McMurdo MET, Guthrie B. Guidelines for people not for diseases: The challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing 2013;42:62–9. 45. Cerreta F, Eichler H-G, Rasi G. Drug Policy for an Aging Population — The European Medicines Agency’s Geriatric Medicines Strategy. N Engl J Med 2012;367(21):1972–4. 46. Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One 2012;7. 47. Nanna MG, Chen ST, Nelson AJ, Navar AM, Peterson ED. Representation of Older Adults in Cardiovascular Disease Trials since the Inclusion across the Lifespan Policy. JAMA Intern Med 2020;180(11):1531–3. 48. Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA - J Am Med Assoc 2011;306(24):2670–2. https://